Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.arGEN-X, a biopharmaceutical company, has partnered with Shire to develop novel therapeutic antibody products against multiple targets.
Subscribe to our email newsletter
Under the agreement, arGEN-X will receive an upfront technology access fee, research funding and preclinical success payments, and in return for its option to develop and commercialize products, Shire will pay fees, milestones and royalties on product sales.
Shire has the option to license the promising leads for further preclinical and clinical development and commercialization worldwide, as per the deal.
arGEN-X, using its Simple Antibody discovery technology, will isolate and characterize human antibodies against the targets that Shire has identified.
arGEN-X CEO Tim Van Hauwermeiren said the company’s Simple Antibody discovery technology delivers antibodies of therapeutic quality against complex targets often intractable with other technologies.
Shire Human Genetic Therapies (HGT) Research and Development Senior Vice President Philip Vickers said collaboration with arGEN-X will bring new therapies to those suffering from rare diseases worldwide.
Financial terms of the agreement have not been disclosed.